ATAI Life Sciences BV (ATAI)vsInsmed Inc (INSM)
ATAI
ATAI Life Sciences BV
$3.54
+4.73%
HEALTHCARE · Cap: $1.29B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 14731% more annual revenue ($606.42M vs $4.09M). ATAI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ATAI
Avoid25
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1773.0% year-over-year
No standout strengths identified
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -390.0% — below average capital efficiency
Earnings declined 96.8%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ATAI
The strongest argument for ATAI centers on Revenue Growth. Revenue growth of 1773.0% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ATAI
The primary concerns for ATAI are Market Cap, Profit Margin, Return on Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ATAI profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
ATAI carries more volatility with a beta of 1.62 — expect wider price swings.
ATAI is growing revenue faster at 1773.0% — sustainability is the question.
ATAI generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ATAI Life Sciences BV
HEALTHCARE · BIOTECHNOLOGY · USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?